BBNX (Beta Bionics) ROE % Adjusted to Book Value: -18.99% (As of Mar. 2026)


BBNX Beta Bionics Inc BBNX
10 GF Score
Price $17.00
! 3 Warning Signs
View Full Analysis

What is Beta Bionics ROE % Adjusted to Book Value?

Beta Bionics BBNX +1.71% 10 ROE % Adjusted to Book Value is -18.99% as of Mar. 2026. GuruFocus rates BBNX with a GF Score™ of 10/100. The stock has 3 warning signs investors should review.

Beta Bionics's ROE % for the quarter that ended in Mar. 2026 was -31.34%. Beta Bionics's PB Ratio for the quarter that ended in Mar. 2026 was 1.65. Beta Bionics's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was -18.99%.

Beta Bionics ROE % Adjusted to Book Value Related Terms

Beta Bionics ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Beta Bionics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beta Bionics ROE % Adjusted to Book Value Chart

Beta Bionics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
0.00 0.00 0.00 -73.73

Beta Bionics Quarterly Data
Dec22 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -198.34 -10.44 -6.42 -3.94 -18.99

BBNX vs CBLL, SIBN, TCMD: ROE % Adjusted to Book Value Comparison

For the Medical Devices subindustry, Beta Bionics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Beta Bionics ROE % Adjusted to Book Value vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Beta Bionics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Beta Bionics's ROE % Adjusted to Book Value falls into.


BBNX
10GF Score
Beta Bionics Inc BBNX
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Beta Bionics ROE % Adjusted to Book Value Calculation

Beta Bionics's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-346.51% / 4.70
=-73.73%

Beta Bionics's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-31.34% / 1.65
=-18.99%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -18.99% mean?
Beta Bionics (BBNX) has a ROE % Adjusted to Book Value of -18.99% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Beta Bionics and its competitors.
Is Beta Bionics' ROE % Adjusted to Book Value too high?
Beta Bionics' current ROE % Adjusted to Book Value is -18.99%. Overall, Beta Bionics has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Beta Bionics' ROE % Adjusted to Book Value compare to CBLL and SIBN?
Beta Bionics' ROE % Adjusted to Book Value of -18.99% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Medical Devices & Instruments company?
A good ROE % Adjusted to Book Value depends on the Medical Devices & Instruments industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Beta Bionics and its competitors. Beta Bionics's current ROE % Adjusted to Book Value is -18.99%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beta Bionics stock overvalued right now?
Beta Bionics (BBNX) has a current ROE % Adjusted to Book Value of -18.99%. The current ROE % Adjusted to Book Value is -18.99%. Beta Bionics' overall GF Score™ is 10/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Beta Bionics (BBNX), the current ROE % Adjusted to Book Value is -18.99% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Beta Bionics Business Description

Address 11 Hughes, Irvine, CA, USA, 92618
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.
10GF Score

Get the complete analysis for BBNX

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$17.00
Price